Ursa Brown‐Glaberman
Impact in
-
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 27
- Cancer Treatment and Pharmacology 14
- HER2/EGFR in Cancer Research 12
- Lung Cancer Research Studies 4
- Neutropenia and Cancer Infections 4
-
- Advanced Breast Cancer Therapies 11
- Co-authors
- Melanie Royce (3 shared papers)Alison Stopeck (8 shared papers)Zoneddy Dayao (5 shared papers)William J. Gradishar (4 shared papers)Hope S. Rugo (2 shared papers)Pavani Chalasani (7 shared papers)Bryan A. Faller (2 shared papers)Ellis Levine (2 shared papers)
- Journals
- Journal of Clinical Oncology (15 papers)Cancer Research (5 papers)Annals of Oncology (3 papers)Clinical Breast Cancer (1 paper)Disease Markers (1 paper)
- Partner nations
- United StatesSpainFrance
In The Last Decade
Ursa Brown‐Glaberman
34 papers receiving 393 citations
Peers
Comparison fields: 5 of 62
- Oncology 186
- Cancer Research 73
- Pulmonary and Respiratory Medicine 84
- Molecular Biology 140
- Genetics 20
Countries citing papers authored by Ursa Brown‐Glaberman
This map shows the geographic impact of Ursa Brown‐Glaberman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ursa Brown‐Glaberman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ursa Brown‐Glaberman more than expected).
Fields of papers citing papers by Ursa Brown‐Glaberman
This network shows the impact of papers produced by Ursa Brown‐Glaberman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ursa Brown‐Glaberman. The network helps show where Ursa Brown‐Glaberman may publish in the future.
Co-authors
The 25 scholars most cited alongside Ursa Brown‐Glaberman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 38 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2021 | 82 | |
| 2 | 2020 | 41 | |
| 3 | 2012 | 35 | |
| 4 | 2019 | 27 | |
| 5 | HER2-targeted therapy for early-stage breast cancer: a comprehensive review. | 2014 | 20 |
| 6 | 2021 | 18 | |
| 7 | 2016 | 18 | |
| 8 | 2019 | 15 | |
| 9 | 2022 | 11 | |
| 10 | 2019 | 11 | |
| 11 | 2021 | 11 | |
| 12 | 2021 | 10 | |
| 13 | 2021 | 10 | |
| 14 | 2022 | 9 | |
| 15 | 2018 | 9 | |
| 16 | 2023 | 7 | |
| 17 | 2022 | 7 | |
| 18 | 2023 | 6 | |
| 19 | 2008 | 6 | |
| 20 | 2021 | 5 |
About Ursa Brown‐Glaberman
Ursa Brown‐Glaberman is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Molecular Biology, Radiology, Nuclear Medicine and Imaging and Cancer Research, having authored 38 papers that have together received 396 indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (14 papers), HER2/EGFR in Cancer Research (12 papers), Advanced Breast Cancer Therapies (11 papers), Monoclonal and Polyclonal Antibodies Research (4 papers), Lung Cancer Research Studies (4 papers), Neutropenia and Cancer Infections (4 papers), Breast Cancer Treatment Studies (3 papers) and Cancer Genomics and Diagnostics (2 papers). The work is most often cited by research in Oncology (186 citations), Cancer Research (73 citations), Pulmonary and Respiratory Medicine (84 citations), Molecular Biology (140 citations) and Genetics (20 citations). Ursa Brown‐Glaberman has collaborated with scholars based in United States, Spain and France. Frequent co-authors include Melanie Royce, Alison Stopeck, Zoneddy Dayao, William J. Gradishar, Hope S. Rugo, Pavani Chalasani, Bryan A. Faller, Ellis Levine, Roisín M. Connolly and G. Thomas Budd. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Annals of Oncology, Clinical Breast Cancer and Disease Markers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.